According to the review of approximately 300,000 patients by Sikander Ailawadhi, MD, Oncologist, Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, and colleagues, there was also significant heterogeneity in practice patterns across all characteristics studied.
An interrupted time-series analysis by David Merola, PharmD candidate, Bernard J. Dunn School of Pharmacy, Shenandoah University, Winchester, VA, and colleagues, showed a significant increase in missed workdays per month after the initial diagnosis of multiple myeloma among patients who received oral or injectable cancer therapy.
Treatment with ivosidenib, an IDH1 inhibitor, resulted in an objective response rate of 41.6% in a phase 1 dose-escalation and expansion clinical trial of patients with relapsed or refractory acute myeloid leukemia and IDH1 mutation, according to data presented at ASH 2017.
AONN+ is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. This particular meeting was all about metrics.
Advocacy usually begins with personal crisis and the need for support, but it eventually moves on to sharing experiences and information with others, speaking out in public forums, and working to influence change, suggested Musa Mayer, breast cancer survivor and advocate, at the recent ESMO International Consensus Conference for Advanced Breast Cancer in Lisbon, Portugal.
To effectively address socioeconomic disparities in healthcare, it is critical that we improve our understanding of the material, psychosocial, and behavioral dimensions of financial well-being, said Reginald D. Tucker-Seeley, MA, ScM, ScD, at the 2017 AACR Science of Cancer Health Disparities Conference.
As the number of patients receiving immune checkpoint blockade grows, the combination of radiation and immunotherapy has become increasingly relevant, particularly in the palliative care setting, where radiation therapy is used to treat painful lesions or brain metastases.
The combination of the investigational drug quizartinib plus azacitidine (Vidaza) or low-dose cytarabine has substantial activity in patients with myeloid leukemias and FLT3 mutations.
At the ACCC National Oncology Conference in October 2017, Brianne Joseph, LPI, brought the audience to their feet with a compelling message for those involved in cancer care.
Results 1 - 10 of 443